GuiZhou SanLi Pharmaceutical Co.,Ltd
Shanghai Stock ExchangeTotal Valuation
GuiZhou SanLi Pharmaceutical Co.,Ltd carries a market capitalization of 5.17B, placing it among publicly traded companies globally. Its enterprise value stands at 5.43B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 5.17B |
| Enterprise Value | 5.43B |
Share Statistics
GuiZhou SanLi Pharmaceutical Co.,Ltd currently has 409.80M shares outstanding.
| Shares Outstanding | 409.80M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
GuiZhou SanLi Pharmaceutical Co.,Ltd trades at a trailing price-to-earnings ratio of 20.38. The price-to-sales ratio is 2.54, and the price-to-book ratio stands at 3.79.
| PE Ratio | 20.38 |
| PS Ratio | 2.54 |
| PB Ratio | 3.79 |
| P/TBV Ratio | 6.21 |
| P/FCF Ratio | 128.15 |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, GuiZhou SanLi Pharmaceutical Co.,Ltd trades at an EV/EBITDA multiple of 18.99 and an EV/FCF ratio of 114.47. The EV/Sales ratio of 2.82 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 18.99 provides insight into valuation relative to core operating earnings.
| EV / Sales | 2.82 |
| EV / EBITDA | 18.99 |
| EV / EBIT | 18.99 |
| EV / FCF | 114.47 |
Financial Position
GuiZhou SanLi Pharmaceutical Co.,Ltd maintains a current ratio of 1.42, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 50.05, indicating elevated leverage, while an interest coverage ratio of 27.17 demonstrates strong ability to service its debt obligations.
| Current Ratio | 1.42 |
| Quick Ratio | 0.29 |
| Debt / Equity | 50.05 |
| Debt / EBITDA | 2.71 |
| Interest Coverage | 27.17 |
Financial Efficiency
GuiZhou SanLi Pharmaceutical Co.,Ltd posts a return on equity of 19.20 and a return on invested capital of 10.72.
| Return on Equity (ROE) | 19.20 |
| Return on Assets (ROA) | 8.09 |
| Return on Invested Capital (ROIC) | 10.72 |
| Return on Capital Employed (ROCE) | 11.59 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 1.80 |
Taxes
Over the trailing twelve months, GuiZhou SanLi Pharmaceutical Co.,Ltd has paid 32.80M in income taxes, reflecting an effective tax rate of 11.73.
| Income Tax | 32.80M |
| Effective Tax Rate | 11.73 |
Stock Price Statistics
GuiZhou SanLi Pharmaceutical Co.,Ltd's stock has gained approximately 8.31933% over the past 52 weeks. The 50-day moving average sits at 13.67, while the 200-day moving average is 12.35.
| Beta (5Y) | N/A |
| 52-Week Price Change | 8.31933% |
| 50-Day Moving Average | 13.67 |
| 200-Day Moving Average | 12.35 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, GuiZhou SanLi Pharmaceutical Co.,Ltd generated 1.93B in revenue and converted that into 240.03M in net income, yielding earnings per share of 0.59. EBITDA reached 286.05M, while operating income came in at 286.05M.
| Revenue | 1.93B |
| Gross Profit | 1.34B |
| Operating Income | 286.05M |
| Pretax Income | 279.56M |
| Net Income | 240.03M |
| EBITDA | 286.05M |
| EBIT | 286.05M |
| Earnings Per Share (EPS) | 0.59 |
Balance Sheet
GuiZhou SanLi Pharmaceutical Co.,Ltd holds 303.05M in cash and equivalents against 775.25M in total debt, resulting in a net debt position of 438.78M. Total book value stands at 1.29B, with working capital of 440.15M providing operational flexibility.
| Cash & Cash Equivalents | 303.05M |
| Total Debt | 775.25M |
| Net Debt | 438.78M |
| Equity (Book Value) | 1.29B |
| Book Value Per Share | 3.08 |
| Working Capital | 440.15M |
Cash Flow
After subtracting -38.17M in capital expenditures, free cash flow totaled -38.17M - equivalent to -0.09 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -38.17M |
| Free Cash Flow | -38.17M |
| FCF Per Share | -0.09 |
Margins
GuiZhou SanLi Pharmaceutical Co.,Ltd operates with a gross margin of 69.52, reflecting its pricing power and cost economics. The operating margin of 14.85 and net profit margin of 12.46 provide insight into operational efficiency.
| Gross Margin | 69.52 |
| Operating Margin | 14.85 |
| Pretax Margin | 14.52 |
| Profit Margin | 12.46 |
| EBITDA Margin | 14.85 |
Dividends & Yields
The company's payout ratio of 63.07 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.38 |
| Dividend Yield | N/A |
| Payout Ratio | 63.07 |
| Shareholder Yield | 1.35 |
| FCF Yield | 0.78 |
Scores
GuiZhou SanLi Pharmaceutical Co.,Ltd posts an Altman Z-Score of 4.25, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 4.25 |